GHRH will be assessed as a potential treatment to combat wasting associated with HIV and cancer.
VGX Pharmaceuticals signed a license agreement with Baylor College of Medicine covering a broad range of Growth Hormone Releasing Hormone (GHRH) technology and related intellectual property for application in humans.
VGX thus gains exclusive, worldwide rights to develop the technology for a number of indications, including cachexia in cancer and HIV patients as well as age-related disorders. This agreement broadens the existing relationship between the two organizations.
“The licensed technology will augment our growing early-stage pipeline of DNA-based therapeutics and vaccines being developed at the VGX-immune therapeutics division,” points out J. Joseph Kim, president and CEO of VGX Pharmaceuticals.
“We already have on-going programs in both HIV and cancer, and the development of GHRH as a potential treatment to combat wasting associated with these diseases may represent an important step in the management of these diseases. Our early efficacy data on the use of plasmid-mediated GHRH supplementation for alleviating cancer-cachexia in dogs has proved to be very promising, and this licensing agreement allows us access to further develop the technology for human applications.”
